Portfolio

adivo

Therapeutic Antibodies for Veterinary Medicine

adivo developed a technology platform for the selection of species-specific thera­peutic anti­bodies for veterinary medicine. These anti­bodies had predefined characte­ristics that enabled the generation of lead candidates with optimal functio­nality for dogs and other animals. After the ongoing colla­boration in canine antibody drug discovery since 2021, which was expanded to include adivo’s novel feline antibody library in 2022, the exit to Zoetis Inc. (NYSE:ZTS), the global leader in animal health, took place in 2023.

iMusician Overview Lunaphore